News & Updates

CUPERTINO, CA and ARLINGTON, VA — PyrAmes Inc. has received an investment from March of Dimes, the leading organization fighting for the health of moms and babies, to support development and commercialization of its wearable technology to noninvasively monitor blood pressure, particularly for new mothers and their babies. PyrAmes' goal is to develop more convenient, clinically-accurate, blood pressure monitoring for all patients, including both mothers and babies in order to support enhancing their health before and after childbirth. PyrAmes’ Boppli™ device for critically-ill infants received Breakthrough Device Designation from the US Food & Drug Administration (FDA). (more…)

PyrAmes’ innovative Boppli™ blood pressure device is featured in the journal Sensors, in a paper reporting a clincal study of 81 infants undergoing critical care at Lucile Packard Children’s Hospital Stanford. Sensors is a leading international, peer-reviewed journal on the science and technology of sensors. The paper, Clinical Study of Continuous Non-Invasive Blood Pressure Monitoring in Neonates, highlights the performance of PyrAmes’ novel algorithm-based blood pressure sensor. Boppli is designed to meet the blood pressure monitoring requirements and physical dimensions of small, prematurely-born infants, without external calibration. Boppli uses machine-learning techniques to extract blood pressure values from the shape of the pulse waveform, and is currently being considered for market clearance by the FDA as a Class II medical device. The paper indicates the use of Boppli is feasible for critically ill term and preterm infants with a wide variety of pathologies—from serious cardiac ailments, pre- and post-operative cases, neurologic conditions, and prematurity.

PyrAmes is among only 10 companies chosen to enter the final Technology Assessment phase of the National Institutes of Health (NIH) RADx Tech for Maternal Health Challenge. The goal of the RADx Challenge is to improve maternal health outcomes for those who live in areas lacking access to maternity care through innovative promising home-based or point-of-care diagnostic devices, wearables, and other remote sensing technologies. PyrAmes’ submission, Non-invasive, Continuous Blood Pressure Monitoring for Postpartum Maternal Health, focuses on its Bosimi™ platform, a noninvasive, wearable sensor designed to monitor blood pressure of women in their postpartum period, when the risk of maternal mortality is highest. (more…)

PyrAmes has been awarded first place in the Early Commercialization Innovation Track in Bear Institute's second annual Pediatric Accelerator Challenge for Kids (PACK). The Bear Institute for Health Innovation is a partnership between Children's National Hospital and Oracle Health Cerner Corporation using HIT to improve the quality of care for children. The PACK awards recognize pediatric digital health innovations of start-up and early-stage companies working to bring innovative technologies to market for children.

SW National Pediatric Device Innovation Consortium recognizes Boppli™ platform for pediatric medical device innovation CUPERTINO, CA and HOUSTON, TX, October 21, 2022 – The Southwest National Pediatric Device Innovation Consortium (SWPDC) awarded PyrAmes $25,000 for its Boppli platform— a non-invasive wearable sensor intended for neonatal ICU patients for continuous blood pressure monitoring with minimal skin contact, which serves as a potential alternative to arterial catheters and inflatable cuffs. The American Academy of Pediatrics (AAP) Section on Advances in Therapeutics and Technology (SOATT) annually recognizes pediatric device innovation. A great need currently exists for medical devices designed specifically for children, which is most likely a result of economic, clinical, and regulatory challenges, as well as a lack of established mechanisms for joining pediatric device ideas with qualified individuals/programs and industry partners to create innovative and needed pediatric devices. (more…)

PyrAmes’ novel Boppli™ device enables continuous, noninvasive blood pressure monitoring (cNIBP) for the hospital’s most fragile patients. PROVIDENCE, RI and CUPERTINO, CA, September 13, 2022 — Sentec and PyrAmes have established a commercial partnership to bring Boppli, PyrAmes’ first-of-its-kind continuous noninvasive blood pressure device, to neonatal intensive care teams throughout the United States. Boppli has received Breakthrough Device Designation from the US Food & Drug Administration (FDA) and will be available after FDA 510(k) clearance, which is anticipated in the first half of 2023. “We are excited to join forces with Sentec to commercialize our Boppli product,” said Xina Quan, PhD, Co-Founder and CEO of PyrAmes. “This important step enables us to bring our breakthrough technology to market and transform patient care. We believe Sentec is an ideal partner for us in the NICU, given our companies’ shared mission and focus on noninvasive technologies to enable better healthcare delivery.”In the neonatal intensive care unit (NICU) today, a baby’s blood pressure is either monitored continuously through an invasive arterial catheter or intermittently through cuff measurements. Both techniques present certain clinical challenges. The Boppli™ platform offers a new solution to overcome those challenges. (more…)

PyrAmes chosen from 1,300+ applicants to collaborate with LG on innovative connected health products. CUPERTINO, CA, February 10, 2022 -- PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced its selection by the LG Electronics North American Innovation Center, LG NOVA in its inaugural cohort of startups selected in its large-scale Mission for the Future global challenge competition. Chosen from a group of over 1,300 applicants, the “First 50” companies represent new developments in several areas including Connected Health, and will work with the LG NOVA team on their business concepts. (more…)

The PyrAmes Boppli™ device is featured on page 11 in the Winter 2022 edition of Neonatal Intensive Care: The Journal of Perinatology-Neonatology. The article focuses on how the Boppli is being developed to meet the need for continuous, non-invasive blood pressure monitoring in the neonatal intensive care unit (NICU).

Plug and Play Japan and its 49 corporate partners have selected PyrAmes for its global accelerator program, including 67 companies from Japan, the U.S., Canada, India, the United Kingdom, Spain, and more. PyrAmes receives business development resources in the program’s Health track, focusing on Plug and Play’s interest in sensors and wearables. Plug and Play Japan is a subsidiary of Plug and Play; a global innovation platform headquartered in Silicon Valley. Its major strength is to provide consortium-type programs with its extensive global network.

PyrAmes’ breakthrough blood pressure sensor is featured in Sensors, the leading international, peer-reviewed journal on the science and technology of sensors. The paper, Advances in Non-Invasive Blood Pressure Monitoring, highlights the added value of PyrAmes’ novel algorithm-based blood pressure sensor which uses machine-learning techniques to extract blood pressure values from the shape of the pulse waveform. The paper reports results from preliminary studies on a range of patient populations and discusses the accuracy and limitations of this capacitive-based technology and its potential application in hospitals and communities.